The Cutting Edge of Medicine: An Interview With Alejandro Alva, MD

Psychiatric Times June 3, 2024
Leah Kuntz, Alejandro Alva, MD

In advance of the June 4 FDA Advisory Committee Meeting on MDMA-assisted therapy, we sat down with Alejandra Alva, MD, to get his first impressions.

CLINICAL CONVERSATIONS

The US Food and Drug Administration (FDA) Advisory Committee Meeting will meet on June 4, 2024, to review investigational MDMA-assisted therapy for posttraumatic stress disorder (PTSD). In our effort to gauge clinician reactions, Psychiatric Times sat down with Alejandro Alva, MD, to learn more on his thoughts about the potential of MDMA, other therapeutic advances, and the future of psychiatry.

PT: Your practice is inclusive, and you are noted as a bicultural clinician. How do you think cultural values and norms will impact patients’ views of MDMA as part of clinical care?

Alejandro...

Today's Sponsors

Today's Sponsor